Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
A clinical trial update describing a real-world study on treatment experiences for breast, lung, ovarian cancer, multiple myeloma, and acute…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
A multicenter prospective observational cohort study in patients with multiple myeloma to evaluate how cancer-directed treatment and medicat…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Elranatamab in Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial of Elranatamab for relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care [NA]
This clinical trial update describes a University of Miami-sponsored study evaluating how Leukemia & Lymphoma Society services affect patien…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma [Phase 2]
Phase 2 trial evaluating pre-transplant purging and post-transplant MRD-guided maintenance therapy with elranatamab in high-risk multiple my…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
A study by Memorial Sloan Kettering Cancer Center aims to identify barriers to cellular therapies for people with plasma cell disorders, inc…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating carfilzomib-based chemotherapy mobilization for autologous stem cell transplants in multiple myeloma.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
This clinical trial will investigate the real-world usage of HyQvia in adults with multiple myeloma and secondary immunodeficiency. The stud…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
Pfizer is conducting a real-world study of elranatamab for refractory multiple myeloma in Taiwan, which is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 open-label study of belumosudil mesylate, alone and in combination with dexamethasone, in p…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating a triplet regimen of carfilzomib, Iberdomide (CC-220), and dexamethasone (…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen [Phase 3]
A Phase 3 trial evaluating whether an olanzapine-containing regimen can prevent delayed chemotherapy-induced nausea and vomiting after autol…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma [Phase 1]
Phase 1 study evaluating the combination of venetoclax and tocilizumab for relapsed or refractory t(11;14) multiple myeloma.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating the safety, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants wit…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib [Phase 1, Phase 2]
A Phase 1/2 clinical trial assessing Etentamig (ABBV-383) as an IV infusion, alone or in combination with Daratumumab, Lenalidomide, Dexamet…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) [NA]
A clinical trial update describing the Italian Tumor Chemogenomic Profiler (IT-TCP), an integrative multi-omics and functional platform to d…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant [Phase 2]
A Phase 2 clinical trial update evaluating busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in patients with hematologi…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating MRD-guided BCMA/CD3 bispecific antibody treatment after stem cell transplant in newly diagnosed multiple…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
This clinical trial explores an AI-driven morphological subtyping of myeloma single cells to predict FISH abnormalities, and the study is cu…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of BMS-986453 in Newly Diagnosed Multiple Myeloma [Phase 1]
This is a Phase 1 clinical trial evaluating BMS-986453 in newly diagnosed multiple myeloma. The study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers
The study investigates cachexia frequency in ambulatory cancer patients and the psychological burden on patients and their primary caregiver…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
A study investigating an individualized frailty-tailored therapy (DynaFiT) for elderly patients with newly diagnosed multiple myeloma is cur…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study evaluating adverse events of intravenous Etentamig (ABBV-383) in adults with relapsed or refractory multiple myeloma is curr…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: National Longitudinal Cohort of Hematological Diseases
Recruiting for a national longitudinal cohort study of hematological diseases sponsored by the Institute of Hematology & Blood Diseases Hosp…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) [Phase 2]
This document provides a Phase 2 clinical trial update on Anitocabtagene-autoleucel for relapsed or refractory multiple myeloma (iMMagine-1)…